title: Limited phenotypic effects of selectively augmenting the SMN protein in the neurons of a mouse model of severe spinal muscular atrophy.
abstract: The selective vulnerability of motor neurons to paucity of Survival Motor Neuron (SMN) protein is a defining feature of human spinal muscular atrophy (SMA) and indicative of a unique requirement for adequate levels of the protein in these cells. However, the relative contribution of SMN-depleted motor neurons to the disease process is uncertain and it is possible that their characteristic loss and the overall SMA phenotype is a consequence of low protein in multiple cell types including neighboring spinal neurons and non-neuronal tissue. To explore the tissue-specific requirements for SMN and, especially, the salutary effects of restoring normal levels of the protein to neuronal tissue of affected individuals, we have selectively expressed the protein in neurons of mice that model severe SMA. Expressing SMN pan-neuronally in mutant mice mitigated specific aspects of the disease phenotype. Motor performance of the mice improved and the loss of spinal motor neurons that characterizes the disease was arrested. Proprioceptive synapses on the motor neurons were restored and defects of the neuromuscular junctions mitigated. The improvements at the cellular level were reflected in a four-fold increase in survival. Nevertheless, mutants expressing neuronal SMN did not live beyond three weeks of birth, a relatively poor outcome compared to the effects of ubiquitously restoring SMN. This suggests that although neurons and, in particular, spinal motor neurons constitute critical cellular sites of action of the SMN protein, a truly effective treatment of severe SMA will require restoring the protein to multiple cell types including non-neuronal tissue.
authors.affiliation: Department of Pathology and Cell Biology, Columbia University, New York, New York, United States of America.
authors.forename: Andrew J-H
authors.initials: AJ
authors.lastname: Lee
authors.forename: Tomoyuki
authors.initials: T
authors.lastname: Awano
authors.forename: Gyu-Hwan
authors.initials: GH
authors.lastname: Park
authors.forename: Umrao R
authors.initials: UR
authors.lastname: Monani
mesh_terms: D000818:Animals; D060833:Cellular Microenvironment; D004195:Disease Models, Animal; D005260:Female; D015316:Genetic Therapy; D006801:Humans; D008297:Male; D051379:Mice; D008822:Mice, Transgenic; D009043:Motor Activity; D009046:Motor Neurons / Q000378:metabolism* / Q000473:pathology; D009134:Muscular Atrophy, Spinal / Q000235:genetics* / Q000401:mortality / Q000473:pathology / Q000628:therapy; D009469:Neuromuscular Junction / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D009928:Organ Specificity; D010641:Phenotype; D012720:Severity of Illness Index; D015996:Survival Rate; D055533:Survival of Motor Neuron 1 Protein / Q000235:genetics* / Q000378:metabolism; D013569:Synapses / Q000235:genetics / Q000378:metabolism; D019076:Transgenes
chemical_list: C526472:Smn1 protein, mouse; D055533:Survival of Motor Neuron 1 Protein